| Title |
Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
|
|---|---|
| Published in |
Cochrane database of systematic reviews, February 2014
|
| DOI | 10.1002/14651858.cd005642.pub3 |
| Pubmed ID | |
| Authors |
Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud |
| Abstract |
A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin still represents standard treatment of chronic hepatitis C infection in the majority of patients. However, it is not established which of the two licensed peginterferon products, peginterferon alpha-2a or peginterferon alpha-2b, is the most effective and has a better safety profile. |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 14% |
| Romania | 1 | 5% |
| Ecuador | 1 | 5% |
| Ukraine | 1 | 5% |
| United Kingdom | 1 | 5% |
| Australia | 1 | 5% |
| Belgium | 1 | 5% |
| Canada | 1 | 5% |
| Unknown | 12 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 68% |
| Practitioners (doctors, other healthcare professionals) | 5 | 23% |
| Scientists | 1 | 5% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 169 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 169 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 26 | 15% |
| Student > Ph. D. Student | 22 | 13% |
| Student > Bachelor | 18 | 11% |
| Student > Doctoral Student | 13 | 8% |
| Researcher | 12 | 7% |
| Other | 24 | 14% |
| Unknown | 54 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 32% |
| Nursing and Health Professions | 18 | 11% |
| Psychology | 8 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Economics, Econometrics and Finance | 5 | 3% |
| Other | 20 | 12% |
| Unknown | 59 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2016.
All research outputs
#2,470,126
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#4,996
of 11,499 outputs
Outputs of similar age
#24,263
of 235,822 outputs
Outputs of similar age from Cochrane database of systematic reviews
#95
of 229 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,822 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 229 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.